NGNE
Neurogene Inc.
NASDAQ · Healthcare · Biotechnology · US
$38.60
+2.63%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -27.7%
- EBIT
- -26.8%
- EPS
- -19.0%
- Free cash flow
- -16.9%
- Operating cash flow
- -17.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +4.8%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- -21.4%
- EBIT
- -24.9%
- Net income
- -20.2%
- EPS
- +0.9%
- Free cash flow
- -9.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026